Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Iovance Biotherapeutics, Inc. at current levels.
First approved solid tumor cell therapy with a real commercial ramp, priced like it's still pre-revenue. The setup is asymmetric.
Where IOVA is headed
Amtagvi is the first and only one-time cell therapy approved for a solid tumor. That sentence still hasn't been fully absorbed by a market that lumped Iovance into the 'cash-burning cell therapy' bucket and walked away. By late 2027, the picture looks different. Authorized Treatment Centers should clear 200 active sites globally, with EU approval extending the addressable melanoma pool by roughly 60% versus US-only. Run-rate revenue in the $700M to $900M zone is achievable if patient throughput per center reaches the 8-12 annual infusions management has been guiding toward, and the manufacturing facility in Philadelphia (iCTC) keeps pulling vein-to-vein time below 30 days.
Read the full Compass Direction on IOVA
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $3.82).
See the full IOVA analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Iovance Biotherapeutics, Inc. at current levels. First approved solid tumor cell therapy with a real commercial ramp, priced like it's still pre-revenue. The setup is asymmetric.
What is IOVA's Compass Score?
Iovance Biotherapeutics, Inc. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for IOVA?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the IOVA page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.